Granules India will hold a meeting of the Board of Directors of the Company on 29 January 2019.

Powered by Capital Market - Live News

Granules India announced that USFDA has approved the ANDA filed by Granules Pharmaceuticals Inc., subsidiary of Granules India, through its US agent First Time US Generic LLC, for Methylphenidate HydrochlorideExtended-Release Tablets USP, 10 mg and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug “Ritalin SR Sustained-Release Tablets, 20 mg” of Novartis Pharmaceuticals Corporation. Granules Pharmaceuticals, Inc. shall market anddistribute the product shortly.

Powered by Capital Market - Live News

Granules India has allotted 75,000 equity shares in consequent to exercise of stock options under ESOS 2009.

Powered by Capital Market - Live News

Granules India announced that the Board of Directors of the Company at its meeting held on 29 October 2018, inter alia, have recommended the second interim dividend of Rs 0.25 per equity Share (i.e. 25%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News